PineBridge Investments L.P. boosted its stake in shares of United Therapeutics Corp. (NASDAQ:UTHR) by 13.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,025 shares of the biotechnology company’s stock after buying an additional 362 shares during the period. PineBridge Investments L.P.’s holdings in United Therapeutics Corp. were worth $320,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of UTHR. Scopia Capital Management LP increased its position in shares of United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock valued at $470,154,000 after buying an additional 1,370,698 shares during the period. Emerald Acquisition Ltd. bought a new position in shares of United Therapeutics Corp. during the second quarter valued at about $47,352,000. Norges Bank bought a new position in shares of United Therapeutics Corp. during the fourth quarter valued at about $65,955,000. Thompson Siegel & Walmsley LLC boosted its position in shares of United Therapeutics Corp. by 140.3% in the second quarter. Thompson Siegel & Walmsley LLC now owns 567,786 shares of the biotechnology company’s stock valued at $60,140,000 after buying an additional 331,476 shares in the last quarter. Finally, AJO LP boosted its position in shares of United Therapeutics Corp. by 13.8% in the second quarter. AJO LP now owns 2,141,541 shares of the biotechnology company’s stock valued at $226,832,000 after buying an additional 258,931 shares in the last quarter.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 123.47 on Thursday. United Therapeutics Corp. has a 12-month low of $97.52 and a 12-month high of $164.04. The stock’s 50 day moving average is $124.17 and its 200-day moving average is $116.07. The stock has a market cap of $5.37 billion, a PE ratio of 5.97 and a beta of 1.46.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share for the quarter, beating analysts’ consensus estimates of $3.22 by $1.33. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The company earned $412.60 million during the quarter, compared to analyst estimates of $395.15 million. During the same quarter last year, the business posted $2.55 EPS. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. Equities analysts expect that United Therapeutics Corp. will post $15.82 EPS for the current year.

Several equities analysts recently issued reports on UTHR shares. Argus reiterated a “hold” rating on shares of United Therapeutics Corp. in a research report on Tuesday, August 23rd. Zacks Investment Research upgraded shares of United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $126.00 price target on the stock in a research report on Tuesday, July 26th. Wedbush reiterated an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corp. in a research report on Thursday, July 28th. Jefferies Group reiterated a “hold” rating and set a $120.00 price target on shares of United Therapeutics Corp. in a research report on Friday, July 29th. Finally, JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating on the stock in a research report on Friday, July 29th. Nine analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $135.64.

In other news, Director Christopher Patusky sold 5,000 shares of the business’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $122.73, for a total value of $613,650.00. Following the completion of the sale, the director now owns 5,000 shares in the company, valued at approximately $613,650. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,249 shares of the business’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $125.78, for a total transaction of $157,099.22. Following the completion of the sale, the chief executive officer now owns 1,389 shares of the company’s stock, valued at approximately $174,708.42. The disclosure for this sale can be found here. Corporate insiders own 7.50% of the company’s stock.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corp. (NASDAQ:UTHR).

Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.